DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience.

A. K. Slade, N. Sadoul, L. Shapiro, L. Chojnowska, J. P. Simon, R. C. Saumarez, B. Dodinot, A. J. Camm, W. J. McKenna, E. Aliot

Department of Cardiological Sciences, St George's Hospital Medical School, London.

BACKGROUND--DDD pacing has been advocated as an effective treatment for drug refractory obstructive hypertrophic cardiomyopathy. This study reports the outcome of pacing in 56 patients with refractory symptoms referred to four tertiary centres. METHODS--Core data on symptoms, drug burden, and left ventricular outflow tract gradient were recorded. Patients underwent a temporary pacing study with optimisation of the atrioventricular (AV) delay for greatest gradient reduction without haemodynamic compromise. Patients were assessed after implantation in terms of changes in symptoms, drug load, and outflow tract gradient. RESULTS--56 patients underwent pacing assessment. The mean (SD) left ventricular outflow tract gradient before pacing was 78 (31) mm Hg. At temporary study the mean (SD) left ventricular outflow tract gradient was 38 (24) mm Hg with a median (range) optimised sensed AV delay of 65 (25-125) ms. Fifty three patients were implanted and followed up for a mean (SD) of 11 (11) months. The median (range) programmed sensed AV delay was 60 (31-200) ms. Left ventricular outflow tract gradient at follow up was 36 (25) mm Hg. Forty four patients had improved functional class. Although a correlation (r = 0.69) was shown between acute and chronic left ventricular outflow tract gradient reduction, there was no correlation between magnitude of gradient reduction and functional improvement, and no appreciable change in pharmacological burden. CONCLUSION--This series confirms symptomatic improvement after DDD pacing in hypertrophic cardiomyopathy. There remains, however, a discrepancy between perceived symptomatic benefit and modest objective improvement. Furthermore, the optimal outcome has been achieved only with continued pharmacological treatment. Current methods of temporary evaluation do not predict functional outcome which seems to be independent of the magnitude of gradient reduction.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Maron, B. J., Maron, M. S., Wigle, E. D., Braunwald, E. (2009). The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.. J Am Coll Cardiol 54: 191-200 [Abstract] [Full Text]  
• Fifer, M. A., Vlahakes, G. J. (2008). Management of Symptoms in Hypertrophic Cardiomyopathy. Circulation 117: 429-439 [Full Text]  
• Maron, B. J. (2002). Hypertrophic Cardiomyopathy: A Systematic Review. JAMA 287: 1308-1320 [Abstract] [Full Text]  
• Gadler, F. (2001). Pacing in obstructive hypertrophic cardiomyopathy. Eur Heart J Suppl 3: L32-L37 [Abstract]  
• Maron, B. J., McKenna, W. J., Elliott, P., Spirito, P., Frenneaux, M. P., Keren, A., Cecchi, F., Borggrefe, M., Williams, W. G., Fananapazir, L. (1999). Hypertrophic Cardiomyopathy. JAMA 282: 2302-2303 [Full Text]  
• O'Rourke, R. A. (1999). Cardiac Pacing : An Alternative Treatment for Selected Patients With Hypertrophic Cardiomyopathy and Adjunctive Therapy for Certain Patients With Dilated Cardiomyopathy. Circulation 100: 786-788 [Full Text]  
• Kass, D. A., Chen, C.-H., Talbot, M. W., Rochitte, C. E., Lima, J. A. C., Berger, R. D., Calkins, H. (1999). Ventricular Pacing With Premature Excitation for Treatment of Hypertensive-Cardiac Hypertrophy With Cavity-Obliteration. Circulation 100: 807-812 [Abstract] [Full Text]  
• Maron, B. J., Nishimura, R. A., McKenna, W. J., Rakowski, H., Josephson, M. E., Kieval, R. S. (1999). Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy : A Randomized, Double-Blind, Crossover Study (M-PATHY). Circulation 99: 2927-2933 [Abstract] [Full Text]  
• Park, M. H., Gilligan, D. M., Bernardo, N. L., Topaz, O. (1999). Symptomatic Hypertrophic Obstructive Cardiomyopathy: The Role of Dual-Chamber Pacing. ANGIOLOGY 50: 87-94 [Abstract]  
• Pak, P. H., Maughan, W. L., Baughman, K. L., Kieval, R. S., Kass, D. A. (1998). Mechanism of Acute Mechanical Benefit From VDD Pacing in Hypertrophied Heart : Similarity of Responses in Hypertrophic Cardiomyopathy and Hypertensive Heart Disease. Circulation 98: 242-248 [Abstract] [Full Text]  
• Braunwald, E. (1997). Induced Septal Infarction : A New Therapeutic Strategy for Hypertrophic Obstructive Cardiomyopathy. Circulation 95: 1981-1982 [Full Text]  
• Goodwin, J F (1997). Sudden cardiac death in the young. BMJ 314: 843-843 [Full Text]  
• Spirito, P., Seidman, C. E., McKenna, W. J., Maron, B. J. (1997). The Management of Hypertrophic Cardiomyopathy. NEJM 336: 775-785 [Full Text]  
• (1996). DDD Pacing and Hypertrophic Disease. Journal Watch Cardiology 1996: 9-9 [Full Text]